Tag: events

MONTREAL, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news release date July 30, 2025, the Company voluntarily applied for and the Company’s principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) dated July 30, 2025, under National Policy 12-203 Management Cease Trade Orders (“NP 12-203”) and provided the Company with an extension to file its annual financial statements for the period ended March 31, 2025, including the related management’s discussion and analysis, and related certifications on or before July 29, 2025 (collectively the “Annual Financial Filings”). The deadline has now been extended to on or before September 29, 2025.

DALLAS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- HF Sinclair Corporation (NYSE and NYSE Texas: DINO) (the “Corporation”) today announced the final results and expiration of its previously announced cash tender offer (the “Tender Offer”) to purchase any and all of its outstanding notes listed in the table below (collectively, the “Notes” and each a “Series” of Notes). Capitalized terms used in this news release and not defined herein have the meanings given to them in the Offer to Purchase, dated August 11, 2025 (the “Offer to Purchase”).

SAN DIEGO, CA, Aug. 15, 2025 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ: RVYL) ("RYVYL” or the "Company") today announced the retirement of Chairman and Co-founder Ben Errez, effective August 31, 2025. RYVYL is repositioning its business to focus on crypto treasury management, beginning with a core strategy centered on building a crypto treasury to support long-term growth.

WOODS CROSS, Utah, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Sky Quarry Inc. (NASDAQ: SKYQ) ("Sky Quarry" or the "Company"), an integrated energy solutions company focused on sustainable resource recovery, today reported its financial and operational results for the second quarter ended June 30, 2025.

FUKUOKA, Japan, Aug. 15, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or the “Company”), a Japanese labor consulting and health services company, today announced the closing of its initial public offering of 1,250,000 Japanese common shares at a public offering price of US$4.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and other offering expenses payable by rYojbaba, was US$5 million. rYojbaba’s Japanese common shares began trading on the Nasdaq Capital Market on August 14, 2025, under the ticker symbol “RYOJ”.

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy^® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.

Not for distribution to United States newswire services or for dissemination in the United States

Hong Kong, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BUUU Group Limited (Nasdaq: BUUU) (the “Company”), an established  meetings, incentives, conferences and exhibitions (“MICE”) solutions provider based in Hong Kong , today announced the closing of its initial public offering (the “Offering”) of 1,500,000 Class A ordinary shares (the “Class A Ordinary Shares”), at a price of $4.00 per Class A Ordinary Share (the “Offering Price”).

CALGARY, Alberta, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Peyto Exploration & Development Corp. (TSX: PEY) ("Peyto") confirms that the monthly dividend with respect to August 2025 of $0.11 per common share is to be paid on September 15, 2025, for shareholders of record on August 31, 2025.

Offering Structured to Accelerate Streamex’s Operational Build-Out, Strategically Allocated with No Warrants

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial